Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech for less than cash value -- Ignore unavailable to you. Want to Upgrade?

To: tom pope who wrote (99)	7/11/2002 1:50:56 PM
From: nigel bates	Read Replies (1) \| Respond to of 684

They also have long term debt of $200MM... In the current environment, my own feeling is that you need to consider cash net of debt to hit the thread description (after all, ELN apparently has cash well in excess of market cap...). 'Biotech for less than cash value, where book value exceeds cash' might be a better metric ? I guess VPHM is kind of an exception given the enormous disparity between cap. and cash on hand. If nothing else, it's a hugely geared bet. (disclaimer, I own stock in both ABGX and ELN) nig